FILTERED RESULTS
FILTERS
Ads Top
DARK MODE
CHART
    Filters
      Symbols
      Sentiment
      Impact
      Search
      FILTERED RESULTS

        

      Upgrade your plan
      ·

      abbv

      ·

      AbbVie Launches Humira on TrumpRx Platform with Significant Discount

      AbbVie has announced the launch of its flagship drug Humira on the TrumpRx platform, offering an 86% discount as part of a pricing agreement with the White House. This initiative aims to reduce out-of-pocket expenses for patients and enhance access to the medication across the United States.

      This pricing strategy represents a significant change in AbbVie's approach to drug pricing in the U.S., particularly following the expiration of Humira's exclusivity. The move is expected to impact the company's market position and investor sentiment as it navigates the evolving pharmaceutical landscape.

      As of now, AbbVie's stock is trading at approximately $206.69, reflecting a one-year return of 14.5%. Investors will be closely monitoring how this new pricing model affects the company's financial performance and overall valuation in the coming months.

      © 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

      Source: KLEA News

      .

      Terra Founder Do Kwon Sentenced to 15 Years in Prison for Fraud